Abstract
Research Objective
To estimate whether manufacturer‐issued prescription drug coupons drive brand utilization over generic alternatives among commercially insured patients.
Study Design
Prescription drug coupons are discounts offered by pharmaceutical manufacturers that reduce a commercial patient’s cost‐sharing responsibility. Manufacturers assert that coupons increase affordability and adherence, while payers and pharmacy benefit managers argue that coupons drive use toward high‐cost drugs when lower cost alternatives may be available, increasing health care system spending. Massachusetts authorized coupon use for commercial patients in 2012, but prohibited coupons for any branded drug that has an “AB‐rated” generic equivalent.
The Massachusetts Health Policy Commission (HPC) investigated the utilization and spending impact of coupon offering for a sample of high spending branded drugs that do not have a generic equivalent but have at least one close therapeutic generic substitute (e.g., an example “set” would be Lyrica and generic gabapentin). We compared the utilization of branded drugs offering coupons versus their generic alternatives in the Massachusetts commercial population with use patterns within the same drug sets in the Massachusetts Medicare program, which prohibits coupon use based on the federal anti‐kickback statute. The hypothesis was that the relative utilization would be similar between the two groups, if coupons had no impact on the rate of branded use. Fourteen sets of drugs were selected that minimized potential age‐related factors that may confound observed utilization differences between the populations. We used pharmacy data from Symphony Health Integrated Dataverse (IDV)® to estimate commercial utilization and coupon offerings, and CMS Part D Prescriber Public Use File for Medicare utilization. Results are presented as a ratio of standardized 30‐day fills of the branded drug to fills of the generic alternatives.
Population Studied
Massachusetts’ Medicare population and a sample of commercially insured patients representing roughly 40% of the Massachusetts commercial market.
Principal Findings
The relative use of the branded drug versus generic alternatives was significantly higher in the commercial population for 10 of the 14 drug sets. For four branded drugs, use trends were similar in commercial and Medicare populations. Across the 14 sets, spending was 18% higher on average per set than it would have been if commercial members used the generic close therapeutic substitutes as often as the Medicare population did, representing approximately $1.4 million in additional spending per drug per year in the data sample. Extrapolating to the entire commercial market in Massachusetts, we estimated that the spending impact would be an excess of approximately $3 million per drug per year, and $44.8 million total per year, for the 14 study drugs.
Conclusions
Coupon availability was associated with moderately higher utilization of branded drugs relative to use of generic close therapeutic substitutes, and higher total spending.
Implications for Policy or Practice
When evaluating drug coupons, policy makers should consider the tradeoffs between increasing access and higher health care system spending.